Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications

The coronavirus disease 2019 (COVID-19) pandemic has reached an unprecedented level. There is a strong demand for diagnostic and serological supplies worldwide, making it necessary for countries to establish their own technologies to produce high-quality biomolecules. The two main viral antigens used for the diagnostics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) are the structural proteins spike (S) protein and nucleocapsid (N) protein. The spike protein of SARS-CoV-2 is cleaved into S1 and S2, in which the S1 subunit has the receptor-binding domain (RBD), which induces the production of neutralizing antibodies, whereas nucleocapsid is an ideal target for viral antigen-based detection. In this study, we designed plasmids, pcDNA3.1/S1 and pcDNA3.1/N, and optimized their expression of the recombinant S1 and N proteins from SARS-CoV-2 in a mammalian system. The RBD was used as a control. The antigens were successfully purified from Expi293 cells, with high yields of the S1, N, and RBD proteins. The immunogenic abilities of these proteins were demonstrated in a mouse model. Further, enzyme-linked immunosorbent assays with human serum samples showed that the SARS-CoV-2 antigens are a suitable alternative for serological assays to identify patients infected with COVID-19.

Citing Articles

Vaccination with Plasmids Encoding the Fusion Proteins D-S1, D-S1N and O-SN from SARS-CoV-2 Induces an Effective Humoral and Cellular Immune Response in Mice.

Mendoza-Ramirez N, Garcia-Cordero J, Hernandez-Galicia G, Moreno-Licona N, Hernandez J, Cabello-Gutierrez C Vaccines (Basel). 2025; 13(2).

PMID: 40006682 PMC: 11860763. DOI: 10.3390/vaccines13020134.

Protein Expression Platforms and the Challenges of Viral Antigen Production.

Sookhoo J, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S Vaccines (Basel). 2025; 12(12.

PMID: 39772006 PMC: 11680109. DOI: 10.3390/vaccines12121344.

Expression and purification of SARS-CoV-2 receptor binding domain in for diagnostic and therapeutic purposes.

Ghaderi H, Shoari A, Salehi S, Eskafi A, Habibi-Anbouhi M, Cohan R Res Pharm Sci. 2024; 19(5):500-508.

PMID: 39691303 PMC: 11648345. DOI: 10.4103/RPS.RPS_93_23.

The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.

Mendoza-Ramirez N, Garcia-Cordero J, Shrivastava G, Cedillo-Barron L J Immunol Res. 2024; 2024:9313267.

PMID: 38939745 PMC: 11208798. DOI: 10.1155/2024/9313267.

Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination.

Zhang Y, Bailey T, Hittmeyer P, Dubois L, Theys J, Lambin P Microb Cell Fact. 2024; 23(1):119.

PMID: 38659027 PMC: 11040787. DOI: 10.1186/s12934-024-02389-y.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Burbelo P, Riedo F, Morishima C, Rawlings S, Smith D, Das S . Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020; 222(2):206-213. PMC: 7313936. DOI: 10.1093/infdis/jiaa273. View

Cordero J, Leon Juarez M, Gonzalez-Y-Merchand J, Cedillo Barron L, Gutierrez Castaneda B . Caveolin-1 in lipid rafts interacts with dengue virus NS3 during polyprotein processing and replication in HMEC-1 cells. PLoS One. 2014; 9(3):e90704. PMC: 3958351. DOI: 10.1371/journal.pone.0090704. View

Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S . Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?. Biomed Res Int. 2020; 2020:4389089. PMC: 7261327. DOI: 10.1155/2020/4389089. View

Johari Y, Jaffe S, Scarrott J, Johnson A, Mozzanino T, Pohle T . Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnol Bioeng. 2020; 118(2):1013-1021. DOI: 10.1002/bit.27615. View

Stuible M, Gervais C, Lord-Dufour S, Perret S, LAbbe D, Schrag J . Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells. J Biotechnol. 2020; 326:21-27. PMC: 7720734. DOI: 10.1016/j.jbiotec.2020.12.005. View

Fenwick C, Croxatto A, Coste A, Pojer F, Andre C, Pellaton C . Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2020; 95(3). PMC: 7925109. DOI: 10.1128/JVI.01828-20. View

Tan Y, Goh P, Fielding B, Shen S, Chou C, Fu J . Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol. 2004; 11(2):362-71. PMC: 371215. DOI: 10.1128/cdli.11.2.362-371.2004. View

Chen C, Chang C, Chang Y, Sue S, Bai H, Riang L . Structure of the SARS coronavirus nucleocapsid protein RNA-binding dimerization domain suggests a mechanism for helical packaging of viral RNA. J Mol Biol. 2007; 368(4):1075-86. PMC: 7094638. DOI: 10.1016/j.jmb.2007.02.069. View

10.

Zinzula L, Basquin J, Bohn S, Beck F, Klumpe S, Pfeifer G . High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. Biochem Biophys Res Commun. 2020; 538:54-62. PMC: 7532810. DOI: 10.1016/j.bbrc.2020.09.131. View

11.

Milewska A, Ner-Kluza J, Dabrowska A, Bodzon-Kulakowska A, Pyrc K, Suder P . MASS SPECTROMETRY IN VIROLOGICAL SCIENCES. Mass Spectrom Rev. 2019; 39(5-6):499-522. PMC: 7228374. DOI: 10.1002/mas.21617. View

12.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View

13.

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View

14.

He F, Deng Y, Li W . Coronavirus disease 2019: What we know?. J Med Virol. 2020; 92(7):719-725. PMC: 7228340. DOI: 10.1002/jmv.25766. View

15.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

16.

Premkumar L, Segovia-Chumbez B, Jadi R, Martinez D, Raut R, Markmann A . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48). PMC: 7292505. DOI: 10.1126/sciimmunol.abc8413. View

17.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

18.

McBride R, Van Zyl M, Fielding B . The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014; 6(8):2991-3018. PMC: 4147684. DOI: 10.3390/v6082991. View

19.

Leung D, Tam F, Ma C, Chan P, Cheung J, Niu H . Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis. 2004; 190(2):379-86. PMC: 7110057. DOI: 10.1086/422040. View

20.

Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C . The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020; 78:185-193. PMC: 7162753. DOI: 10.1016/j.ijsu.2020.04.018. View